Sign In
Buy KALA
$3.54
-0.0700 (-1.94%)
At Close: Jun 22, 2026
KALA Bio Stockholders Elect Directors, Approve 1.5B Share Increase and Potential Reverse Split
04:38am, Sunday, 01'st Feb 2026
KALA BIO (NASDAQ: KALA) held its 2025 annual meeting of stockholders in a virtual format, with Chief Executive Officer David Lazar presiding. Lazar, who also serves as the company's director, chief fi
KALA BIO Settles Approximately $10.6 million of Debt
04:10pm, Monday, 05'th Jan 2026
ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
10:45am, Thursday, 04'th Dec 2025
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of a
Why Did KALA BIO Shares Jump Over 22% After Hours?
12:20am, Thursday, 04'th Dec 2025
KALA BIO shares jumped over 22% after Oxford Finance acquired a 16.5% stake, amid recent leadership changes and continued year-to-date losses.
What Sparked KALA BIO's Nearly 38% Surge Overnight?
12:34am, Wednesday, 26'th Nov 2025
KALA BIO shares surged over 37% in after-hours trading following a private placement, loan settlement, and leadership changes.
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
12:21pm, Wednesday, 08'th Oct 2025
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
Kala Bio downgraded to Neutral from Outperform at Mizuho
09:32am, Tuesday, 30'th Sep 2025
Mizuho downgraded Kala Bio to Neutral from Outperform with a price target of $1.50, down from $30. The firm cites yesterday's negative Phase 2 results for the company's lead asset KPI-012 for the down
Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?
12:00pm, Monday, 29'th Sep 2025
Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade
10:55am, Wednesday, 13'th Aug 2025
The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Kala Bio (KALA) Q2 Loss Widens 15%
08:18am, Friday, 08'th Aug 2025
Kala Bio (KALA -2.19%), a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08:00am, Friday, 08'th Aug 2025
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 mill
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
08:00am, Wednesday, 06'th Aug 2025
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
12:56pm, Friday, 25'th Jul 2025
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on p
KALA BIO to Present at Jefferies Global Healthcare Conference
08:00am, Thursday, 29'th May 2025
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative t
